
Sign up to save your podcasts
Or
In this week’s podcast, John Mandrola, MD, discusses the PROTECTED TAVR trial, renal denervation, left atrial appendage closure and deprescribing aspirin.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I Cerebral Embolic Protection After TAVI
- Clear Stroke Benefit Eludes Embolic Protection: PROTECTED TAVR https://www.medscape.com/viewarticle/980978
- Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement https://www.nejm.org/doi/10.1056/NEJMoa2204961
- Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement https://doi.org/10.1016/j.jacc.2016.10.023
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
- Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
- Randomised Trial Of Intravenous Streptokinase, Oral Aspirin, Both, Or Neither Among 17 187 Cases Of Suspected Acute Myocardial Infarction: Isis-2 https://doi.org/10.1016/S0140-6736(88)92833-4
II Renal Denervation
- Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
- Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial https://doi.org/10.1016/S0140-6736(22)01787-1
- A systematic review, meta-analysis, and meta regression of the sham controlled renal denervation randomized controlled trials https://doi.org/10.1016/j.tcm.2022.05.009
- Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
- A Controlled Trial of Renal Denervation for Resistant Hypertension https://www.nejm.org/doi/10.1056/NEJMoa1402670
III Percutaneous Left Atrial Appendage Occlusion (LAAO)
- Amulet, Watchman 2.5 LAAO Outcomes Neck and Neck at 3 Years https://www.medscape.com/viewarticle/981199
- Consider Life Expectancy When Referring for LAA Closure? https://www.medscape.com/viewarticle/981117
- Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure https://www.jacc.org/doi/full/10.1016/j.jacep.2022.06.012
IV Deprescribing Aspirin
- Deprescribing Aspirin for Warfarin Patients May Reduce Bleeding https://www.medscape.com/viewarticle/981243
- Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796492
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
4.9
826826 ratings
In this week’s podcast, John Mandrola, MD, discusses the PROTECTED TAVR trial, renal denervation, left atrial appendage closure and deprescribing aspirin.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I Cerebral Embolic Protection After TAVI
- Clear Stroke Benefit Eludes Embolic Protection: PROTECTED TAVR https://www.medscape.com/viewarticle/980978
- Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement https://www.nejm.org/doi/10.1056/NEJMoa2204961
- Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement https://doi.org/10.1016/j.jacc.2016.10.023
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
- Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
- Randomised Trial Of Intravenous Streptokinase, Oral Aspirin, Both, Or Neither Among 17 187 Cases Of Suspected Acute Myocardial Infarction: Isis-2 https://doi.org/10.1016/S0140-6736(88)92833-4
II Renal Denervation
- Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
- Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial https://doi.org/10.1016/S0140-6736(22)01787-1
- A systematic review, meta-analysis, and meta regression of the sham controlled renal denervation randomized controlled trials https://doi.org/10.1016/j.tcm.2022.05.009
- Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
- A Controlled Trial of Renal Denervation for Resistant Hypertension https://www.nejm.org/doi/10.1056/NEJMoa1402670
III Percutaneous Left Atrial Appendage Occlusion (LAAO)
- Amulet, Watchman 2.5 LAAO Outcomes Neck and Neck at 3 Years https://www.medscape.com/viewarticle/981199
- Consider Life Expectancy When Referring for LAA Closure? https://www.medscape.com/viewarticle/981117
- Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure https://www.jacc.org/doi/full/10.1016/j.jacep.2022.06.012
IV Deprescribing Aspirin
- Deprescribing Aspirin for Warfarin Patients May Reduce Bleeding https://www.medscape.com/viewarticle/981243
- Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796492
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
130 Listeners
13 Listeners
319 Listeners
160 Listeners
494 Listeners
18 Listeners
272 Listeners
3,321 Listeners
87 Listeners
135 Listeners
1,082 Listeners
54 Listeners
186 Listeners
515 Listeners
320 Listeners
59 Listeners
25 Listeners
8 Listeners
415 Listeners
363 Listeners